Re-Print Non-Aspirin Nsaids Use is Associated with Lowering of Liver Fibrosis Scores in Patients with Fatty Liver Disease

Only a few studies are available with appropriate data on the effects of non-aspirin, non-steroidal anti-inflammatory drugs (NSAID’s) use in patients with fatty liver disease. We performed a retrospective study of 1347 patients with imaging studies that showed fatty liver disease from 2016 through 2019. Then we determined the change in validated indices using Fibrosis-4 (FIB4) and NAFLD fibrosis score (NFS). Patient’s clinical information, including NSAID’s use, was collected at baseline and then yearly. Using generalized linear model, we estimated the association between the non-aspirin NSAID’s use and change in the baseline indices. Non-aspirin NSAID’s use was found to be associated with significant lowering of FIB-4 score (0.596 units lower, p-value <0.0001) and NFS score (0.431 units lower, p-value 0.0027) every year. In this retrospective study of patients with fatty liver disease found on imaging, non-aspirin NSAID’s use was associated with lowering of fibrotic scores, suggesting that non- aspirin containing NSAID’s use might be associated with a lower risk for advanced fibrosis in patients with fatty liver disease. Summary: Non-aspirin NSAID’s use is associated with lowering of hepatic fibrosis scores in patients with fatty liver disease.